If 55,000 people each contribute just $1, Phase 0 of a molecular diagnostics research program focused on endometriosis can begin.
Phase 0 will conduct feasibility experiments to evaluate whether measurable molecular signals associated with endometriosis biology can be detected and analyzed with sufficient reliability to justify larger studies.
The Problem
Endometriosis affects an estimated 190 million people worldwide. Despite its prevalence, diagnosis still relies largely on surgical visualization through laparoscopy, and the average time to diagnosis is commonly reported at 7–10 years.
Increasing evidence suggests that endometriosis reflects a systemic inflammatory disease, involving immune, vascular, and neurological pathways rather than a purely localized gynecologic disorder.
These diagnostic challenges reflect deeper scientific gaps in understanding the biological signals associated with the disease. Advancing that understanding requires carefully designed molecular research capable of generating reliable biological evidence.
What We’re Working On
Veridyn Diagnostics is a women’s health biotechnology company focused on developing molecular diagnostics for gynecologic diseases and related systemic conditions, beginning with endometriosis.
Despite its prevalence, the biological signals associated with endometriosis remain incompletely characterized. This contributes to long diagnostic timelines and continued reliance on invasive procedures.
The current research focuses on identifying and evaluating measurable molecular signals associated with endometriosis biology. Phase 0 feasibility experiments are designed to determine whether these signals can be detected and analyzed with sufficient reliability to justify larger studies.
This work represents the first step in a structured research program designed to generate the biological evidence needed to support future diagnostics development.
While endometriosis is the initial focus, the scientific framework being developed may support investigation of additional gynecologic diseases and related systemic conditions that remain under-recognized or poorly characterized.
The long-term objective is to generate molecular evidence capable of supporting the development of non-invasive diagnostics that improve detection of women’s health conditions.
Who’s Behind the Research
Randi Wood, MB(ASCP)
Founder & Chief Scientific Officer
Randi Wood has spent over a decade developing molecular diagnostic tests within regulated clinical laboratory environments.
Her work includes building laboratories, designing validation frameworks, and implementing assays that meet the rigorous standards required for clinical use. These are the types of diagnostics physicians rely on to guide treatment decisions and healthcare systems depend on to operate safely and effectively.
Veridyn brings that same level of scientific rigor and regulatory discipline to women’s health.
The objective is straightforward: develop diagnostics that are reproducible, clinically deployable, and trusted across the healthcare system.
Why Crowdfunding Is Necessary
Women’s health diagnostics research faces structural underfunding. Historically, less than 2% of NIH funding has gone toward women’s health outside of cancer, and the development of new diagnostics receives an even smaller share.
In endometriosis specifically, federal investment in diagnostic development has been extremely limited. The NIH’s only recent initiative focused on endometriosis diagnostics was a one-time challenge prize, and no new grants have been awarded since late 2025.
This creates a practical barrier for early research. Many grant programs require preliminary biological evidence before funding can be awarded, but generating that evidence requires the very experiments those grants are meant to support.
Crowdfunding helps bridge that gap. Direct public support enables the first feasibility experiments needed to establish whether meaningful molecular signals can be detected.
By contributing, supporters help unlock the foundational evidence that allows future grants, collaborations, and larger research programs to move forward.
What Your Support Will Fund
Your support enables the first feasibility experiments needed to determine whether measurable molecular signals associated with endometriosis can be detected.
Contributions will support:
• Laboratory testing to examine molecular patterns in biospecimens
• Scientific data analysis to identify meaningful biological signals
• Research materials and core services required for molecular experiments
• Independent technical review to ensure analytical rigor
The goal is clear: develop a non-invasive, gold-standard diagnostic test for endometriosis that can dramatically shorten the current 7–10 year diagnostic delay.
With sufficient funding, this research program is designed to move from feasibility to a deployable diagnostic within approximately 24 months of launch.
If this research matters to you, consider contributing $1 and sharing this campaign to help reach the 55,000 supporters needed to begin the work.
Learn more about Veridyn Diagnostics:
Organizer
